Cardiovascular Imaging

Research out of the Cummings School of Veterinary Medicine at Tufts University suggests focused cardiac ultrasound, rather than a full echo workup, might be an effective way of screening for CVD in cats.

The American Society of Nuclear Cardiology, together with eight other nuclear medicine and cardiology societies, have published a consensus document outlining the best practices for imaging and diagnosing cardiac amyloidosis.

Researchers have successfully trained a convolutional neural network to detect congestive heart failure with 100% accuracy using data from just one heartbeat.

Handheld POC echo has proven useful in- and outside of the emergency department, but physicians still have reservations.

Long-term exposure to ambient air pollutants—especially ozone—increase a person’s chance of developing emphysema, according to research published August 13 in JAMA.

A study published in JAMA Network Open August 11 suggests that, despite the growing use of imaging modalities like computed tomography and MRI, echocardiography remains the most popular method for imaging patients with heart failure.

Researchers at Beth Israel Deaconess Medical Center in Boston have developed an imaging technique that allows physicians to diagnose CAD without the risk of a contrast agent.

A study published this week in Circulation: Cardiovascular Imaging details how one Canadian scientist and his team are using 2-minute video selfies to track patients’ blood pressure.

Overall exposure to ionizing radiation for patients undergoing radiofrequency ablation of AFib is “acceptable” in most cases, according to research published in the American Journal of Cardiology—but obese patients are exposed to a higher dose than their normal-weight counterparts.

Researchers at Carnegie Mellon University’s College of Engineering have devised a way to 3D bioprint tissue scaffolds out of collagen, putting them one step closer to the goal of printing a full-sized, functional human heart.

Medtronic and, an AI-driven tech company, have joined forces to promote the adoption of imaging software that could drastically cut the time it takes physicians to identify suspected large vessel occlusion.

Gadobutrol, sold by Bayer under the brand name Gadavist, became the first FDA-approved contrast agent for use in cardiac magnetic resonance imaging on July 15.